Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering. In its latest SEC filing, the company said it was planning to offer 7.5M ...

Closed loop insulin pump therapy lowers the risk for hypoglycemic coma but increases diabetic ketoacidosis risk among patients with T1D.

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in ...

TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...